<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02669615</url>
  </required_header>
  <id_info>
    <org_study_id>PRO00026736</org_study_id>
    <nct_id>NCT02669615</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic Study of Propylene Glycol-Free Melphalan HCl for Myeloablative Conditioning in Multiple Myeloma Patients Undergoing Autologous Transplantation</brief_title>
  <official_title>A Phase II, Open-Label, Pharmacokinetic Study of Propylene Glycol-Free Melphalan HCl for Myeloablative Conditioning in Multiple Myeloma Patients Undergoing Autologous Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical College of Wisconsin</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical College of Wisconsin</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a single-center, open-label study of high-dose Melphalan HCl (hydrochloric
      acid) for injection (propylene glycol-free Melphalan) conducted in 24 patients, who have
      symptomatic multiple myeloma and qualify for autologous stem-cell transplantation (ASCT).

      There will be three distinct evaluation periods in this trial: a pretreatment period, a study
      period and a follow-up period.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OVERVIEW: This study is a single-center, open-label study of high-dose Melphalan HCl for
      injection (propylene glycol free Melphalan) conducted in 24 patients, who have symptomatic
      multiple myeloma and qualify for ASCT.

      There will be three distinct evaluation periods in this trial: a pretreatment period, a study
      period and a follow-up period.

      PRETREATMENT:

      Pretreatment Period Evaluations (Days -30 to -3). Baseline assessments will be collected
      within 30 days of dosing with Melphalan HCl for injection (propylene glycol free), after the
      patient has signed the informed consent. These include clinical and laboratory assessments
      (e.g., medical history and physical examination, hematology, urine analysis, creatinine
      clearance), chest X-ray and vital signs.

      STUDY TREATMENT:

        1. During the study period, patients will receive 200 mg/m^2 of Melphalan HCl for injection
           (propylene glycol free) as a one-time infusion on day

        2. Following one day of rest after the myeloablative Melphalan conditioning (day -1),
           patients will receive an autologous graft with a minimum cell dose of 2 × 106 CD34+
           cells/kg of patient body weight (day 0).

        3. Pharmacokinetic, efficacy and safety evaluations will be performed during the study
           period.

      FOLLOW-UP:

      ASCT Day +1 until Day+100. During the follow-up period, patients will return for daily
      laboratory tests (hematology and basic serum chemistry) and will be evaluated weekly by their
      physicians until the engraftment date, with the final end-of-study evaluation occurring up to
      seven days after engraftment date. During the follow-up period, the tests (e.g., physical
      examination, CBC, vital signs, full serum chemistry panel, bone marrow biopsy) will be
      performed weekly until engraftment (unless otherwise specified).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 1, 2016</start_date>
  <completion_date type="Actual">July 19, 2017</completion_date>
  <primary_completion_date type="Actual">June 9, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax (Pharmacokinetics)</measure>
    <time_frame>Day -2</time_frame>
    <description>Maximum observed plasma concentration. Derived from the individual raw data.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-t (Pharmacokinetics)</measure>
    <time_frame>Day -2</time_frame>
    <description>Area under the plasma concentration-time curve to the last measurable time point (AUC0-t) calculated by the trapezoidal rule. The area under the concentration-time curve (AUC) is calculated to determine the total drug exposure over a period of time.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Transplant-Related Mortality (TRM) Following Autologous Stem-Cell Transplantation (ASCT)</measure>
    <time_frame>100 days</time_frame>
    <description>TRM will be summarized descriptively (death within 100 days without relapse following ASCT).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>Melphalan HCl for injection (propylene glycol free)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive 200 mg/m^2 of Melphalan HCl for injection (propylene glycol free) as a one-time infusion on day 2. Blood samples for the pharmacokinetic (PK) evaluation of melphalan will be collected after melphalan dosing (day -2). Following one day of rest after the myeloablative Melphalan conditioning (day -1), patients will receive an autologous graft with a minimum cell dose of 2 × 106 CD34+ cells/kg of patient body weight (day 0).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Melphalan HCl for injection (propylene glycol free)</intervention_name>
    <description>During the study period, patients will receive 200 mg/m^2 of Melphalan HCl for injection (propylene glycol free) as a one-time infusion on day 2.</description>
    <arm_group_label>Melphalan HCl for injection (propylene glycol free)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with symptomatic multiple myeloma (MM) requiring treatment at or following
             diagnosis.

          -  Patients with MM, who qualify for ASCT therapy, and have received pretransplant
             therapy prior to transplantation.

          -  Adult patients (≥18 years of age) meeting local institutional criteria to receive a
             total Melphalan dose of 200 mg/m^2 as a conditioning regimen.

          -  Patients with an adequate autologous graft, which is defined as an unmanipulated,
             cryopreserved, peripheral blood cell graft containing at least 2 × 106 CD34+ cells/kg,
             based on patient weight.

          -  Patients with adequate organ function, as measured by:

          -  Cardiac: Left ventricular ejection fraction at rest &gt;40% (documented within 30 days
             prior to Day -3).

          -  Hepatic: Bilirubin &lt;2 × the upper limit of normal (ULN) and Alanine
             transaminase/Aspartate transaminase (ALT/AST) &lt;3 × ULN.

          -  Renal: Creatinine clearance &gt;40 mL/min (measured or calculated/estimated).

          -  Pulmonary: Adjusted Diffusing capacity of the lungs for carbon monoxide (DLCO), forced
             expiratory volume in one second (FEV1), forced vital capacity (FVC) &gt;50% of predicted
             value (corrected for hemoglobin level [Hgb]) and documented within prior to day -3.

        Exclusion Criteria:

          -  Patients with systemic AL amyloidosis (immunoglobulin light chain amyloidosis).

          -  Eastern Cooperative Oncology Group (ECOG) performance status ≥2.

          -  Patients with uncontrolled hypertension.

          -  Patients with a serious active bacterial, viral or fungal infection.

          -  Patients with prior malignancies except resected basal cell carcinoma or treated
             cervical carcinoma in situ. Cancer treated with curative intent &gt;5 years previously
             will be allowed. Cancer treated with curative intent &lt;5 years previously will not be
             allowed unless approved by the medical monitor.

          -  Female patients who are pregnant (positive human chorionic gonadotropin [ß-HCG]) or
             breastfeeding.

          -  Female patients of childbearing potential, who are unwilling to use adequate
             contraceptive techniques during and for one month following study treatment with
             Melphalan HCl for injection (propylene glycol free).

          -  Patients seropositive for HIV.

          -  Patients who are unwilling to provide informed consent.

          -  Patients receiving other concurrent anticancer therapy (including chemotherapy,
             radiation, hormonal treatment, or immunotherapy, but excluding corticosteroids) within
             30 days prior to the ASCT or planning to receive any of these treatments prior to
             study discharge.

          -  Patients concurrently participating in any other clinical study.

          -  Patients who are hypersensitive or intolerant to any component of the study drug
             formulation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Parameswaran Hari, MD, MRCP, MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical College of Wisconsin</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Froedtert Hospital and the Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>January 24, 2016</study_first_submitted>
  <study_first_submitted_qc>January 27, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 1, 2016</study_first_posted>
  <results_first_submitted>July 10, 2018</results_first_submitted>
  <results_first_submitted_qc>September 12, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">October 10, 2018</results_first_posted>
  <last_update_submitted>September 12, 2018</last_update_submitted>
  <last_update_submitted_qc>September 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 10, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical College of Wisconsin</investigator_affiliation>
    <investigator_full_name>Parameswaran Hari</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>multiple myeloma</keyword>
  <keyword>Melphalan HCl</keyword>
  <keyword>Autologous Transplantation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melphalan</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>February 20, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/15/NCT02669615/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 20, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/15/NCT02669615/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Melphalan HCl for Injection (Propylene Glycol Free)</title>
          <description>Patients will receive 200 mg/m^2 of Melphalan HCl for injection (propylene glycol free) as a one-time infusion on day 2. Blood samples for the pharmacokinetic (PK) evaluation of melphalan will be collected after melphalan dosing (day -2). Following one day of rest after the myeloablative Melphalan conditioning (day -1), patients will receive an autologous graft with a minimum cell dose of 2 × 106 CD34+ cells/kg of patient body weight (day 0).
Melphalan HCl for injection (propylene glycol free): During the study period, patients will receive 200 mg/m2 of Melphalan HCl for injection (propylene glycol free) as a one-time infusion on day 2.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Melphalan HCl for Injection (Propylene Glycol Free)</title>
          <description>Patients will receive 200 mg/m2 of Melphalan HCl for injection (propylene glycol free) as a one-time infusion on day 2. Blood samples for the pharmacokinetic (PK) evaluation of melphalan will be collected after melphalan dosing (day -2). Following one day of rest after the myeloablative Melphalan conditioning (day -1), patients will receive an autologous graft with a minimum cell dose of 2 × 106 CD34+ cells/kg of patient body weight (day 0).
Melphalan HCl for injection (propylene glycol free): During the study period, patients will receive 200 mg/m2 of Melphalan HCl for injection (propylene glycol free) as a one-time infusion on day 2.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="24"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67" lower_limit="46" upper_limit="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Cmax (Pharmacokinetics)</title>
        <description>Maximum observed plasma concentration. Derived from the individual raw data.</description>
        <time_frame>Day -2</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Melphalan HCl for Injection (Propylene Glycol Free)</title>
            <description>Patients will receive 200 mg/m^2 of Melphalan HCl for injection (propylene glycol free) as a one-time infusion on day 2. Blood samples for the pharmacokinetic (PK) evaluation of melphalan will be collected after melphalan dosing (day -2). Following one day of rest after the myeloablative Melphalan conditioning (day -1), patients will receive an autologous graft with a minimum cell dose of 2 × 106 CD34+ cells/kg of patient body weight (day 0).
Melphalan HCl for injection (propylene glycol free): During the study period, patients will receive 200 mg/m2 of Melphalan HCl for injection (propylene glycol free) as a one-time infusion on day 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax (Pharmacokinetics)</title>
          <description>Maximum observed plasma concentration. Derived from the individual raw data.</description>
          <units>ng/ml</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7380" lower_limit="5220" upper_limit="11200"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC0-t (Pharmacokinetics)</title>
        <description>Area under the plasma concentration-time curve to the last measurable time point (AUC0-t) calculated by the trapezoidal rule. The area under the concentration-time curve (AUC) is calculated to determine the total drug exposure over a period of time.</description>
        <time_frame>Day -2</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Melphalan HCl for Injection (Propylene Glycol Free)</title>
            <description>Patients will receive 200 mg/m^2 of Melphalan HCl for injection (propylene glycol free) as a one-time infusion on day 2. Blood samples for the pharmacokinetic (PK) evaluation of melphalan will be collected after melphalan dosing (day -2). Following one day of rest after the myeloablative Melphalan conditioning (day -1), patients will receive an autologous graft with a minimum cell dose of 2 × 106 CD34+ cells/kg of patient body weight (day 0).
Melphalan HCl for injection (propylene glycol free): During the study period, patients will receive 200 mg/m2 of Melphalan HCl for injection (propylene glycol free) as a one-time infusion on day 2.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-t (Pharmacokinetics)</title>
          <description>Area under the plasma concentration-time curve to the last measurable time point (AUC0-t) calculated by the trapezoidal rule. The area under the concentration-time curve (AUC) is calculated to determine the total drug exposure over a period of time.</description>
          <units>ng*min/ml</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="533552" lower_limit="253780" upper_limit="770538"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Transplant-Related Mortality (TRM) Following Autologous Stem-Cell Transplantation (ASCT)</title>
        <description>TRM will be summarized descriptively (death within 100 days without relapse following ASCT).</description>
        <time_frame>100 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Melphalan HCl for Injection (Propylene Glycol Free)</title>
            <description>Patients will receive 200 mg/m^2 of Melphalan HCl for injection (propylene glycol free) as a one-time infusion on day 2. Blood samples for the pharmacokinetic (PK) evaluation of melphalan will be collected after melphalan dosing (day -2). Following one day of rest after the myeloablative Melphalan conditioning (day -1), patients will receive an autologous graft with a minimum cell dose of 2 × 106 CD34+ cells/kg of patient body weight (day 0).
Melphalan HCl for injection (propylene glycol free): During the study period, patients will receive 200 mg/m2 of Melphalan HCl for injection (propylene glycol free) as a one-time infusion on day 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Transplant-Related Mortality (TRM) Following Autologous Stem-Cell Transplantation (ASCT)</title>
          <description>TRM will be summarized descriptively (death within 100 days without relapse following ASCT).</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>100 days post transplant</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Melphalan HCl for Injection (Propylene Glycol Free)</title>
          <description>Patients will receive 200 mg/m^2 of Melphalan HCl for injection (propylene glycol free) as a one-time infusion on day 2. Blood samples for the pharmacokinetic (PK) evaluation of melphalan will be collected after melphalan dosing (day -2). Following one day of rest after the myeloablative Melphalan conditioning (day -1), patients will receive an autologous graft with a minimum cell dose of 2 × 106 CD34+ cells/kg of patient body weight (day 0).
Melphalan HCl for injection (propylene glycol free): During the study period, patients will receive 200 mg/m2 of Melphalan HCl for injection (propylene glycol free) as a one-time infusion on day 2.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>leukopenia</sub_title>
                <description>Myeloablation as expected</description>
                <counts group_id="E1" events="24" subjects_affected="24" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Parameswaran Hari</name_or_title>
      <organization>Medical College of Wisconsin</organization>
      <phone>4148054600</phone>
      <email>phari@mcw.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

